Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-01-27
1999-05-25
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514824, A61K 3170
Patent
active
059069791
ABSTRACT:
This invention relates to compositions and methods for decreasing the level of serum insulin, triglycerides, cholesterol, and/or free and total testosterone, and/or improving ovulation, and/or increasing progesterone and/or sex hormone binding globulin in mammals. This invention also relates to compositions and methods for treating metabolic diseases characterized by hyperinsulinemia, hyperandrogenism, hyperlipidemia and/or anovulation, such as polycystic ovary syndrome.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 5550166 (1996-08-01), Ostlund et al.
Carmina, E. et al., "Does ethnicity influence the prevalence of adrenal hyperandrogensim and insulin resistance in polycystic ovary syndrome?" Am. J. Obstetrics and Gynecology 167:1807-1812 (1992).
Ciaraldi, T. et al., "Cellular Mechanisms of Insulin Resistance in Polycystic Ovarian Syndrom," J. Clin. Endocrinology and Metabolism 75:577-583 (1992).
Dunaif, A. et al., "Excessive Insulin Receptor Serine Phosphorylation in Cultured Fibroblasts and in Skeletal Muscle," J. Clin. Invest. 96:801-810 (1995).
Dunaif, A. et al., "The Insulin-Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome," J. Clin. Endocrinology and Metabolism 81:3299-3306 (1996).
Eppstein, D. et al., "Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor," Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985).
Hwang, K. et al., "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study," Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980).
Jakubowicz, D. and J. Nestler, "17.alpha.-Hydroxyprogesterone Responses to Leuprolide and Serum Androgens in Obese Women with and without Polycystic Ovary Syndrome after Dietary Weight Loss," J. Clin. Endocrinology and Metabolism 82: 556-560 (Feb. 1997).
Langer, R. et al., "Biocompatibility of polymeric delivery systems for macromolecules," J. Biomed. Materials Res. 15:267-277 (1981).
Langer, R., "Controlled release of macromolecules," Chemtech 12:98-105 (1982).
Nestler, J. and D. Jakubowicz, "Decreases In Ovarian Cytochrome P450c17.alpha. Activity And Serum Free Testosterone After Reduction Of Insulin Secretion In Polycystic Ovary Syndrome," New England J. Med. 335:617-623 (1996).
Sidman, K. et al., "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid," Biopolymers 22:547-556 (1983).
Dialog File 351, Derwent WPI English language abstract for EP 0 052 322. (1982).
Dialog File 351, Derwent WPI English language abstract for JP 58-118008. (JP 60-007934) (1983).
Dialog File 351, Derwent WPI English language abstract for EP 0 088 046. (1983).
Dialog File 351, Derwent WPI English language abstract for DE 3218121. (1983).
Dialog File 351, Derwent WPI English language abstract for EP 0 102 324. (1984).
Dialog File 351, Derwent WPI English language abstract for EP 0 133 988. (1985).
Dialog File 351, Derwent WPI English language abstract for EP 0 142 641. (AU 8433327) (1985).
Insmed Pharmaceuticals, Inc.
Jordan Kimberly
LandOfFree
Compositions and methods for treating metabolic diseases charact does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating metabolic diseases charact, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating metabolic diseases charact will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-401368